Carbidopa and benserazide suppress viability of both bortezomib-sensitive and -resistant multiple myeloma cells via inhibition of cystathionine-β-synthase, an H<sub>2</sub>S-forming enzyme

○Fumiko Sekiguchi

[31P-am314] Carbidopa and benserazide suppress viability of both bortezomib-sensitive and -resistant multiple myeloma cells via inhibition of cystathionine-β-synthase, an H₂S-forming enzyme

○Fumiko Sekiguchi¹, Haruka Moriguchi¹, Yukiho Fukushima¹, Yuriko Iba¹, Tsukasa Hatakeyama¹, Maho Tsubota¹, Shiori Hiramoto¹, Takuya Okada², Naoki Toyooka², Hirokazu Tanaka³, Takashi Ashida³, Itaru Matsumura³, Atsufumi Kawabata¹ (1. Fac. Pharm., Kindai Univ., 2. Fac. Engineer., Univ. Toyama, 3. Fac. Med., Kindai Univ.)

Enter the password to view the abstracts.
The password will be emailed to those who have completed the registration.

Presentation information

[31P-am] Pharmacology 5

[31P-am314] Carbidopa and benserazide suppress viability of both bortezomib-sensitive and -resistant multiple myeloma cells via inhibition of cystathionine-β-synthase, an H₂S-forming enzyme

Password

Presentation information

[31P-am] Pharmacology 5

[31P-am314] Carbidopa and benserazide suppress viability of both bortezomib-sensitive and -resistant multiple myeloma cells via inhibition of cystathionine-β-synthase, an H2S-forming enzyme

Password

[31P-am314] Carbidopa and benserazide suppress viability of both bortezomib-sensitive and -resistant multiple myeloma cells via inhibition of cystathionine-β-synthase, an H₂S-forming enzyme